Literature DB >> 12629517

Wnt signaling in B-cell neoplasia.

Ya-Wei Qiang1, Yoshimi Endo, Jeffrey S Rubin, Stuart Rudikoff.   

Abstract

Wnts comprise a family of secreted proteins that interact with receptors consisting of a Frizzled (Fz) family member alone or complexed with LDL receptor-related proteins (LRP5/6). Wnt signaling plays a crucial role in both development and differentiation, and activation of a 'canonical' Wnt pathway resulting in beta-catenin stabilization is associated with several types of human cancers. To date, little is known about potential Wnt signaling in mature lymphocytes or lymphoid neoplasia. Herein, we have analysed Wnt signaling in mature B cells (lymphomas) and plasma cells (multiple myeloma). Both Fz and LRP5/6 mRNAs were expressed in myeloma lines, but LRP5/6 were not observed in lymphomas. In myelomas, a canonical Wnt signaling pathway was activated following treatment with Wnt-3a as assessed by accumulation of beta-catenin, but beta-catenin levels actually decreased in lymphoma cells. Wnt-3a treatment further led to striking morphological changes in myeloma cells accompanied by rearrangement of the actin cytoskeleton. Morphological changes were associated with a second Wnt pathway dependent on Rho activation. These results suggest that Wnt responsiveness is a stage-specific phenomenon in B-cell development and that the morphological changes associated with Wnt signaling may play a role in the motility and metastatic potential of myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629517     DOI: 10.1038/sj.onc.1206239

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

Review 1.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

Review 2.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  Evidence for the osteosarcoma stem cell.

Authors:  C Parker Gibbs; Padraic P Levings; Steven C Ghivizzani
Journal:  Curr Orthop Pract       Date:  2011-07

4.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

5.  Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway.

Authors:  Gary G Zhai; Rajeev Malhotra; Meaghan Delaney; Douglas Latham; Ulf Nestler; Min Zhang; Neelanjan Mukherjee; Qinhui Song; Pierre Robe; Arnab Chakravarti
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

6.  Anthelmintic pyrvinium pamoate blocks Wnt/β-catenin and induces apoptosis in multiple myeloma cells.

Authors:  Fang Xu; Yingjie Zhu; Yuhong Lu; Zhi Yu; Jun Zhong; Yangqiu Li; Jingxuan Pan
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

Review 7.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

8.  Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma.

Authors:  Ya-Wei Qiang; Yu Chen; Nathan Brown; Bo Hu; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Br J Haematol       Date:  2009-11-24       Impact factor: 6.998

9.  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.

Authors:  Ya-Wei Qiang; John D Shaughnessy; Shmuel Yaccoby
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

10.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.

Authors:  Desheng Lu; Yandong Zhao; Rommel Tawatao; Howard B Cottam; Malini Sen; Lorenzo M Leoni; Thomas J Kipps; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.